Data updated: May 26, 2026
ABELCET (amphotericin b)
Infectious Disease
Approved 1995-11-20
2
Indications
--
Phase 3 Trials
2
Priority Reviews
30
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1995-11-20
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE, LIPID COMPLEX
ABELCET Approval History
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 1995 to 2013 · 1 indication expansions
Dec 2013 SUPPL Priority
Mfg · Manufacturing (CMC)
Aug 2013 SUPPL Priority
Mfg · Manufacturing (CMC)
Sep 1999 SUPPL Priority
Mfg · Manufacturing (CMC)
Aug 1999 SUPPL Priority
Mfg
Aug 1999 SUPPL Priority
Mfg
Jun 1999 SUPPL Priority
Mfg
Aug 1997 SUPPL Priority
Mfg
Oct 1996 SUPPL Priority
Efficacy
Sep 1996 SUPPL Priority
Mfg
Nov 1995 ORIGINAL Priority
New Ingredient
What ABELCET Treats
2 FDA approvalsOriginally approved for its first indication in 1995 . Covers 2 distinct patient populations.
- Other (2)
Other
(2 approvals)- • Approved indication (Nov 1995) Priority
- • Approved indication (Oct 1996) Priority
📋
Clinical Trial Registry
7 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02629419 CAMB results posted | MB-70004 16-I-0002 | Ph 2 | completed | CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis |
| NCT06413056 | micafungin in neonates | Ph 4 | completed | Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection |
| NCT04031833 EnACT | MB-70007 | Ph 1, Ph 2 | completed | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) |
| NCT00885703 results posted | A5225 (HiFLAC) 10149, ACTG A5225 | Ph 1, Ph 2 | completed | High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals |
| NCT03112031 | 28CN | Ph 2 | completed | Treatment With Tamoxifen in Cryptococcal Meningitis |
| NCT04018417 | 2019-005 | Ph 2, Ph 3 | withdrawn | Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections. |
| NCT01615809 results posted | FSJD-ABELNEB-2010 | Ph 2 | completed | Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ABELCET FDA Label Details
Track ABELCET with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.